Effect of Intravenous Mannitol on Anterior Chamber Depth and Intraocular Pressure.

May 18, 2026 updated by: Muhammad Aamir Latif

Effect of Intravenous Mannitol on Anterior Chamber Depth and Intraocular Pressure in Patients Before Cataract Surgery.

Local data regarding the effectiveness and safety of mannitol has been scarce. Therefore, the current study was planned, aiming to compare the change in mean anterior chamber depth and intraocular pressure (IOP) and to determine the frequencies of perioperative complications during cataract surgery in groups receiving mannitol versus placebo.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The literature shows that the effectiveness of mannitol in decreasing intraocular pressure (IOP) varies widely. Although it rapidly lowers IOP in the majority of people, clinical results and the extent of the reduction differ depending on a number of factors. Mannitol can be detrimental for patients with pulmonary edema or severe heart failure (congestive heart failure) because it quickly draws fluid into the bloodstream, increasing intravascular volume. In addition to contributing to the local literature, the results of this study will aid in determining the true efficacy and safety of mannitol.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab Province
      • Islamabad, Punjab Province, Pakistan, 44000
        • Pakistan Air Force (PAF) hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients of any gender
  • Aged 30-80 years
  • Undergoing cataract surgery

Exclusion Criteria:

  • Patients with glaucoma, uveitis, or corneal pathology
  • With trauma
  • Previously had surgery
  • With exfoliation syndrome
  • Had iridotomies
  • Had use of sympathetic α1 antagonist

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group-A
After employing standard protocol for dilatation, intravenous mannitol at 1g/kg over a period of 30 minutes was administered to the patients.
Drug: Mannitol
After employing standard protocol for dilatation, intravenous mannitol at 1g/kg over a period of 30 minutes was administered to the patients.
Placebo Comparator: Group-B
After employing standard protocol for dilatation, patients were given a placebo.
Drug: Placebo
After employing standard protocol for dilatation, patients were given a placebo.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the intraocular pressure
Time Frame: 45 minutes
The change in the intraocular pressure, measured in mmHg, was noted at post-intervention and compared to the baseline.
45 minutes
Change in the anterior chamber depth
Time Frame: 45 minutes
The change in the anterior chamber depth, measured in mm, was noted at post-intervention and compared to the baseline.
45 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Muhammad Aamir Latif

Investigators

  • Principal Investigator: Muhammad Irtiza, Pakistan Air Force (PAF) Hospital Islamabad
  • Study Director: Muhammad Azam, FCPS, Pakistan Air Force (PAF) Hospital Islamabad

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2024

Primary Completion (Actual)

February 28, 2025

Study Completion (Actual)

February 28, 2025

Study Registration Dates

First Submitted

May 18, 2026

First Submitted That Met QC Criteria

May 18, 2026

First Posted (Actual)

May 22, 2026

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 18, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Dr-Irtiza-Islamabad

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data can be shared on a reasonable request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cataract

Clinical Trials on Mannitol

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe